Yumanity Therapeutics Inc expected to post a loss of 84 cents a share - Earnings Preview

Kineta

02/08/2021 21:58

* Yumanity Therapeutics Inc  YMTX.OQ   YMTX.O  is expected
to show a rise in quarterly revenue when it reports results on
August 4 (estimated). 
* The Boston, Massachusetts-based company is expected to report
revenue of $2.267 million, according to the mean estimate from 3
analysts, based on Refinitiv data.  
​* Refinitiv's mean analyst estimate for Yumanity Therapeutics
Inc is for a loss of 84 cents per share. For the same quarter
last year, the company reported a loss of $3.40 per share.
* The current average analyst rating on the shares is "buy" and
the breakdown of recommendations is 3 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell." 
* The mean earnings estimate of analysts had risen by about 0.6%
in the last three months. ​
* Wall Street's median 12-month price target for Yumanity
Therapeutics Inc is $36​, about 74.8% above​ its last closing
price of $9.08. ​​​
* Previous quarterly performance (using preferred earnings
measure in US dollars). ​
 QUARTER       STARMINE    REFINITIV  ACTUAL    BEAT,   SURPRI
 ENDING        SMARTESTIM  IBES                 MET,    SE %
               ATE®        ESTIMATE             MISSED  
 Mar. 31 2021  -0.84       -0.83      -0.85     Missed  -2.4
 Dec. 31 2020              -2.80      3.96      Beat    241.4
 Sep. 30 2020  -3.48       -3.60      -2.20     Beat    38.9​
 Jun. 30 2020  -4.27       -4.25      -3.40     Beat    20
 Mar.          -5.34​      -5.10      -3.80     Beat    25.5​
 31​ 2020​                                              
 Dec. 31 2019  -5.09       -5.75      -4.60     Beat    20​
 Sep. 30 2019  -8.12       -8.10      -5.00     Beat    38.3
 Jun. 30 2019  -7.59       -7.53      -7.80     Missed  -3.5
 This summary was machine generated August 2 at 20:58 GMT.  All
figures in US dollars unless otherwise stated